

FIG. 1



Formula (I)



Formula (II)

FIG. 2




FIG. 3A



21
16
11
6
1
Fold of Non-treated Control
1
100
10000
Concentration, nM
DSR-6434
AXC-863
AXC-940 DL
AXC-936 DL
AXC-937 DL
AXC-939 DL

FIG. 3B



21
16
11
6
1
Fold of Non-treated Control
1
100
10000
Concentration, nM
DSR-6434
AXC-863
AXC-938 DL
AXC-946 DL
AXC-945 DL

FIG. 4



0.8
0.6
0.4
0.2
0.0
OD655nm
0.001
0.01
0.1
1
10
100
1000
ISAC Conc (nM)
HER2-TLR7 agonist control
HER2-AXC863
HER2-AXC879
HER2 mAb

FIG. 5



RAW Blue + SKBR3
5
4
3
2
1
0
Fold change of OD655nm
0.001
0.01
0.1
1
10
100
1000
ISAC Conc (nM)
HER2-WT Fc
HER2-ADE Fc
HER2-PVA Fc
RSV Isotype control

FIG. 6



Fold Change of OD655nm
5
4
3
2
1
0
0.001
0.01
0.1
1
10
100
1000
ISAC Conc (nM)
HER2-HA114
HER2-HA143
HER2-HL166
HER2-LK149
HER2-LV205
RSV Isotype control

FIG. 7A



OD655nm
0.8
0.6
0.4
0.2
0.0
0.001
0.01
0.1
1
10
100
1000
Treatment (nM)
AXC905 (D)
HER2-AXC913
HER2-AXC914
HER2-mAb
SK-BR-3
AXC905 (D)
HER2-AXC913
HER2-AXC914
HER2-mAb
HCC1806

FIG. 7B



0.8
0.6
0.4
0.2
0.0
OD450nm
0.001 0.01 0.1 1 10 100 1000
Treatment (nM)
AXC905 (D)
HER2-AXC922
HER2-AXC924
HER2-mAb
SK-BR-3
HER2-AXC924
HER2-mAb
HCC1806

FIG. 7C



0.8
0.6
0.4
0.2
0.0
0.001 0.01 0.1 1 10 100 1000
Treatment (nM)
HER2-AXC925
SK-BR-3
HCC1806

FIG. 8A



SK-BR-3 HCC1806
HER2-913
HER2-924
HER2-947
HER2-949
mAb
Fold Change
Treatment (nM)
0.001 0.01 0.1 1 10 100 1000
0 1 2 3 4

FIG. 8B



SK-BR-3 HCC1806
HER2-913
HER2-924
HER2-936
HER2-937
HER2-938
HER2-939
HER2-940
HER2-941
HER2-945
mAb
Fold Change
Treatment (nM)
0.001 0.01 0.1 1 10 100 1000
0 1 2 3 4

FIG. 8C



Fold Change of OD655nm
5
4
3
2
1
0
0.001 0.01 0.1 1 10 100 1000
Treatment (nM)
SK-BR-3
HER2-879
HER2-946
HER2-950
HER2-951
HER2-952
HER2 mAb
HCC1806
HER2-879
HER2-946
HER2-950
HER2-951
HER2-952
mAb

FIG. 9A



Fold Change of OD655nm
10
8
6
4
2
0
0.001 0.01 0.1 1 10 100 1000
Treatment (nM)
HER2-958
HER2-959
HER2-961
HER2-962
HER2-913
HER2 mAb
HER2-924
HER2-945
HER2-937
HER2-879
AXC878 (D)

FIG. 9B



Fold Change of OD655nm
10
8
6
4
2
0
0.001 0.01 0.1 1 10 100 1000
Treatment (nM)
HER2-958
HER2-959
HER2-961
HER2-962
HER2-913
HER2 mAb
HER2-924
HER2-945
HER2-937
HER2-879
AXC878 (D)

FIG. 10



Fold Change of ADCC Activity
2.0
1.5
1.0
0.5
0.0
SKBR3
HCC1806
NT
HER2
HER2-879
Isotype-879

FIG. 11



HLA-DR
10000
8000
6000
4000
2000
0
MFI
NT
HER2 mAb
HER2-879
PSMA-879

FIG. 12



A
B
C
D
CD86
CD209/DC-SIGN

FIG. 13A




FIG. 13B




FIG. 13C




FIG. 14A




FIG. 14B




FIG. 15A




FIG. 15B




FIG. 15C




FIG. 15D




FIG. 16A




FIG. 16B




FIG. 16C




FIG. 16D




FIG.17A




FIG. 17B




FIG. 17C




FIG. 17D




FIG. 18A




FIG. 18B




FIG. 18C




FIG. 19A




FIG. 19B




FIG. 20A




FIG. 20B




FIG. 21A




FIG. 21B




FIG. 22A




FIG. 22B




FIG. 23




FIG. 24A




FIG. 24B




FIG. 24C




FIG. 25




FIG. 26A




FIG. 26B




FIG. 27




FIG. 28




FIG. 29A




FIG. 29B




FIG. 30A





FIG. 30B


Body Weight (g)
26
24
22
20
18
10
20
30
40
Days After Inoculation
Gr.1 Control
Gr.2 RSV 10 mpk
Gr.3 TROP2-AXC879 (1 mpk)
Gr.4 TROP2-AXC879 (3 mpk)
Gr.5 TROP2-AXC879 (10 mpk)